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Semaglutide is a human glucagon-like peptide-1 (GLP-1) analogue that is in development for the
treatment of type 2 diabetes. In the pre-approval cardiovascular outcomes trial SUSTAIN
6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy
(DR) complications vs placebo. GLP-1 receptor (GLP-1R) expression has previously been demon-
strated in the retina in animals and humans; however, antibodies used to detect expression have
been documented to be non-specific and fail to detect the GLP-1R using immunohistochemistry
(IHC), a problem common for many G-protein coupled receptors. Using a validated GLP-1R anti-
body for IHC and in situ hybridization for GLP-1R mRNA in normal human eyes, GLP-1Rs were
detected in a small fraction of neurons in the ganglion cell layer. In advanced stages of DR,
GLP-1R expression was not detected at the protein or mRNA level. Specifically, no GLP-1R
expression was found in the eyes of people with long-standing proliferative DR (PDR). In conclu-
sion, GLP-1R expression is low in normal human eyes and was not detected in eyes exhibiting
advanced stages of PDR.
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1 | INTRODUCTION
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide bene-
fits for people with type 2 diabetes (T2D), including improvements in
glycaemic control and body weight, and two GLP-1RAs have also
shown cardiovascular (CV) risk reduction. The efficacy and safety of
semaglutide in patients with T2D were assessed in the SUSTAIN clini-
cal trial programme, in which semaglutide provided superior improve-
ments in glycated haemoglobin (HbA1c) and body weight vs
comparators, and furthermore showed CV risk reduction in SUSTAIN
6, a 2-year pre-approval CV outcomes trial.1,2 In SUSTAIN 6, semaglu-
tide was associated with a higher rate of diabetic retinopathy
(DR) complications.2 DR complications were an adjudicated composite
secondary endpoint, based on time from randomization to the first
occurrence of need for retinal photocoagulation or treatment with
intravitreal agents, diagnosis of vitreous haemorrhage, or onset of
diabetes-related blindness. Unlike most phase III T2D trials, in
SUSTAIN 6, patients with advanced diabetes and high risk of CV dis-
ease were included, with no upper limit on HbA1c.2 A recently pub-
lished paper from SUSTAIN 6 concludes that early worsening of DR is
a known phenomenon associated with the rapidity and magnitude of
improvement in glycaemic control with insulin, and the DR findings in
SUSTAIN 6 are consistent with this.3
The glucagon-like peptide-1 receptor (GLP-1R) is a G-protein
coupled receptor (GPCR) that shows high homology among spe-
cies. Detection of GPCRs by immunohistochemistry (IHC) is
technically difficult and many antibodies have been shown to be
unspecific.4,5 As a result, journals have introduced rigorous
reporting requirements for IHC results.6 When reporting cellular
localizations for a GPCR it is important to use not only IHC,
but also a complementary technology, such as in situ hybridiza-
tion (ISH) or in situ ligand binding (ISLB). For cellular localiza-
tion, ISLB is not optimal and ISH is preferred to complement
IHC. Similarly to other GPCRs, data on GLP-1R expression with
IHC has been subject to controversy because of non-specific
antibodies.7,8 Many published papers describe studies with poly-
clonal antibodies that have subsequently been withdrawn from
the market because of a confirmed lack of specificity.9 Specific
monoclonal antibodies are available, and use of these in IHC,
combined with ISLB, has provided thorough characterization of
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GLP-1R expression in tissues of particular interest, such as the
pancreas, kidney and thyroid.10,11
We have now investigated GLP-1R expression in normal human
eyes and eyes of patients with advanced stages of proliferative DR
(PDR) by IHC with the thoroughly validated monoclonal antibody
3F52. The IHC analysis was confirmed by the detection of GLP-1R
mRNA by RNAScope ISH. This technique has become state-of-art for
ultra-sensitive and specific mRNA detection.12
2 | METHODS
2.1 | Tissue samples
The human eye samples were formalin-fixed, paraffin-embedded sec-
tions from patients with PDR (n = 5, mean SD [range] age 47 12
[28-67] years; two men; all had a diabetes duration >10 years and all
had received laser photocoagulation) and controls (n = 4, mean SD
[range] age 62 8 [49-70] years; three men). All patients had enucle-
ation carried out because of pain and had PDR according to the Inter-
national Clinical Diabetic Retinopathy Severity Scale outlined by the
American Academy of Ophthalmology.13 The control subjects had
eyes enucleated as a result of extraocular cancer treatment; eyes were
clinically and histologically classified as normal, and no patients
received radiotherapy. Human positive control tissue was provided by
Asterand Bioscience (Royston, UK). The study was performed as a col-
laboration between the Department of Pathology at Rigshospitalet
(Copenhagen, Denmark) and Novo Nordisk A/S and was approved by
the Regional Committee on Health Research Ethics for the Capital
Region of Denmark (H-15014782). Tissue from rhesus monkeys was
used to optimize the protocol before use on the human samples. Sam-
pling from rhesus monkeys was performed according to regulations
specified under the Protection of Animals Act by the European Union
authority. The tissues were paraformaldehyde-fixed and paraffin-
embedded.
2.2 | Immunohistochemistry and
immunofluorescence
Sections (3-5-μm thickness) were cut and antigen retrieval was per-
formed in Tris-EGTA buffer (pH 9.0) at 99C for 15 minutes. The
slides were preincubated for 30 minutes in protein-blocking solution
(FP1012; Perkin Elmer, Waltham, Massachusetts) and incubated over-
night at 4C with the primary antibodies diluted in the protein block-
ing solution. The primary antibodies were detected with BrightVision
Poly horseradish peroxidase (HRP) anti-mouse IgG (DPVM55HRP;
Immunologic) followed by Discovery Purple HRP (760-229; Roche,
Basel, Switzerland). The antibodies used were mouse anti-GLP-1R (2.5
or 7.5 μg/mL, 3F52; Novo Nordisk A/S, Denmark) and mouse IgG1
isotype control (MAB002; R&D Systems, St Paul, Minneapolis).
For immunofluorescence, the following additional antibodies were
applied: rabbit anti-neuronal nuclei (NeuN [0.3 μg/mL, Ab177487;
Abcam, Cambridge, UK]), rabbit anti-GFAP (0.2 μg/mL, Z0334; DAKO,
Glostrup, Denmark); rabbit IgG isotype control (910801; BioLegend,
San Diego, California); Alexa488-conjugated goat anti-rabbit IgG
(2 μg/mL, A-11034; Thermo Fisher Scientific, Waltham, Massachu-
setts); and Alexa594-conjugated goat anti-mouse IgG (8 μg/mL, A-
11032; Thermo Fisher Scientific). All NeuN positive cells in the gan-
glion cell layer (GCL) in one eye section per donor were counted in
the GLP-1R IHC stains.
2.3 | In situ hybridization
Single and duplex ISH were performed with the RNAscope 2.5 VS
Reagent Kit (322260; Advanced Cell Diagnostics, Newark, California)
and RNAscope 2.5 LS Duplex Reagent Kit (322440; Advanced Cell
Diagnostics), respectively. Pretreatment for single ISH was 8 minutes
at 97C and 12-minute protease treatment and, for duplex ISH,
10 minutes at 88C and 10-minute protease treatment. The probes
applied were all targeting human mRNA; that is, GLP-1R (519829,
519828), platelet endothelial cell adhesion molecule-1 (PECAM1;
548458), RNA polymerase II subunit A (POLR2A; 310459, 310458)
and melanopsin (OPN4; 504998), all from Advanced Cell Diagnostics.
Dihydrodipicolinate reductase (DAPB; 312039VS, 312038LS) codes
for bacterial mRNA, and served as a negative control probe. For all
experiments GLP-1R was detected by Fast Red-based kits; in duplex
stain, GLP-1R was detected in combination with a green chromogen
(322550; Advanced Cell Diagnostics).
All bright field pictures were obtained with a Hamamatsu Nano-
zoomer 2.0 HT slide scanner (pixels 1024 × 1024) and all fluorescent
pictures were obtained with a Zeiss AXIO, Imager 2 epifluorescent
microscope (pixels 1388 × 1040).
3 | RESULTS
3.1 | GLP-1R expression in normal human eyes
In normal human eyes (n = 4), GLP-1Rs were detected in single cells
in the retinal GCL (Figure 1A). GLP-1Rs were not detected in the reti-
nal and choroid vasculature, the retinal pigment epithelium, or in any
other ocular structure. The GLP-1R-positive cells constituted <1% of
the cells in the GCL, and only 0-4 GLP-1R-positive cells were detected
per eye section (4/1547, 3/1598, 0/1448 and 2/1479 GLP-1R-
positive neurons/ NeuN-positive neurons in the GCL). The GLP-1R-
positive cells were morphologically characterized by having a round
nucleus and horizontal processes. The detection of only a low number
of GLP-1R-positive cells in the retina could not be explained by low
sensitivity of the staining protocol because the positive control tis-
sues, stained in parallel with the eye sections, showed the expected
pattern of GLP-1R expression. Strong GLP-1R staining was detected
in the Brunner's glands in the duodenum (human) and in the pancre-
atic islets (monkey). Weaker GLP-1R immunoreactivity was detected
in acinar cells in the pancreas and at the vascular pole in the renal
cortex (monkey; Figure 1C,E). GLP-1R mRNA was detected in single
cells in the GCL (n = 4; Figure 1G). Staining with positive (POLR2A)
and negative (DAPB) control probes showed a good signal-to-noise
ratio with the applied protocol and sufficient mRNA integrity for
performing ISH (Figure 1H,I). No GLP-1R mRNA was detected out-
side the GCL.
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To characterize the GLP-1R-positive cells in the GCL, double
immunofluorescence was performed. GLP-1Rs were detected in cells
co-labelled with the neuronal marker NeuN (Figure S1A), but not in
glial fibrillary acidic protein (GFAP)-positive glial cells (Figure S1B;
n = 3). No co-labelling was detected when the primary antibodies
were replaced with isotype control antibodies (data not shown). Based
on the position and low frequency of the GLP-1R-positive cells, they
could be melanopsin-expressing retinal ganglion cells. To address this,
duplex ISH for GLP-1R and OPN4 (coding for melanopsin) was per-
formed. Only one out of 13 GLP-1R-positive cells co-localized with
melanopsin (n = 4; Figure S1C).
3.2 | GLP-1R expression in PDR
The expression of GLP-1Rs was studied in eye sections from patients
with advanced stages of PDR (n = 5). Different histopathological find-
ings representative for DR, including neuronal cell loss, retinal pigment
epithelium proliferation and areas of neovascularization, were present
in the sections. The five donor sections had 287, 96, 326, 732 and
520 neurons, respectively, in the GCL. The GLP-1R protein could not
be detected in the retina or any other ocular structure in sections
from patients with PDR. Areas with neovascularization and no GLP-
1R expression are shown in Figure 2A,B. Furthermore, GLP-1R mRNA
was not detected in the PDR sections, although strong staining was
obtained in the sections with positive control probes (Figure 2C,D).
4 | DISCUSSION
We investigated GLP-1R expression in human eyes with and without
PDR. GLP-1Rs were detected in normal human eyes, with full agree-
ment between the detection of GLP-1R protein and mRNA. GLP-1Rs
were only detected in single cells confined to the GCL of the retina.
No expression was detected in the retinal or choroidal vasculature or
in the retinal pigment epithelium. Based on the morphology of the
GLP-1R-positive cells and our cell-identification analysis, the GLP-1R-
positive cells appeared to have a neuronal phenotype. Disruption of
the circadian rhythm in patients with DR has been reported,14 and
melanopsin-expressing retinal ganglion cells are known for regulating
the circadian rhythm.15 The low frequency and position of the GLP-
1R-positive cells suggest that these cells could represent melanopsin-
expressing retinal ganglion cells15; however, we only detected a lim-
ited overlap between GLP-1R and melanopsin in the normal human
eyes. A publication using db/db mice has indicated GLP-1RAs may
confer neuroprotection in DR.16 As animal models should always be
interpreted with caution, it is likely that studies in other animal models
reflecting other aspects of DR would be needed for a full understand-
ing of the potential of GLP-1RAs in DR.17 A DR outcome study in
patients with type 2 diabetes will be conducted with semaglutide.
Neither GLP-1R protein nor mRNA was detected in eye sections
from patients with advanced stages of PDR. Importantly, we did not
detect any signs of GLP-1R expression in areas characterized by neo-
vascularization. The lack of GLP-1R expression in the GCL may be
FIGURE 1 Detection of single glucagon-
like peptide-1 receptor (GLP-1R)-positive
cells in the human retina. A, detection of
GLP-1R protein by immunohistochemistry
(IHC) in single cells of the ganglion cell layer
(GCL) in the human retina (pink colour).
C–E, detection of GLP-1R protein in C,
Brunner's glands and D, rhesus monkey
kidney and E, pancreas, serving as positive
control tissues. B, and F, no
immunoreactivity was detected when the
antibody against GLP-1R was substituted
with an isotype control antibody, either in
the eye (B) or in the control tissues (F).
G, detection of GLP-1R mRNA by in situ
hybridization (ISH) in single cells localized in
the GCL. H and I, the positive control probe
(POLR2A) (H) confirmed the preservation of
mRNA in the sections and the negative
bacterial control probe (DAPB) (I) showed
the level of unspecific staining. The control
probes showed a good signal-to-noise ratio.
All sections were counterstained with
haematoxylin. One eye section was stained
per donor. Arrow heads, GLP-1R-positive
cells; arrows, GLP-1R-positive process;
GCL, ganglion cell layer; INL, inner nuclear
layer; ONL, outer nuclear layer; v, blood
vessel. Scale bars represent 50 μm (B) and
100 μm (I) and apply to A´ and B, and C–I,
respectively
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explained by partial loss of retinal ganglion cells at these stages of the
disease.18 Because of the expression pattern of GLP-1Rs detected in
normal eyes, GLP-1Rs are likely to be present in the GCL at less
advanced stages of the disease where the neuronal cell loss is less
profound. To what extent GLP-1R expression is induced in other
structures at earlier stages of DR or PDR was not addressed, but the
present data do not suggest ectopic expression of GLP-1Rs in any
ocular structure.
Other studies using rodent animal models reflecting early diabetic
eye disease have suggested that GLP-1RAs could prevent the occur-
rence of DR, and show GLP-1R expression in the retina, in the GCL,
inner nuclear layer and outer nuclear layer16; however, the GLP-1R
expression methodology applied in those studies with IHC is not valid
because they used antibody ab39072, which has been withdrawn
from the market as a result of a confirmed lack of specificity.9 With
the limited GLP-1R expression and the confinement to neurons in
GCL in normal human eyes it can be hypothesized that GLP-1RAs are
unlikely to play a direct role via the GLP-1R in the worsening of
established DR.
The present data are in contrast to the literature suggesting more
abundant retinal expression of GLP-1Rs.16 In the present study, we
used IHC with a thoroughly validated GLP-1R antibody, the inclusion
of negative control antibodies and positive control tissues. Further-
more, the IHC analysis was confirmed by the detection of GLP-1R
mRNA by ISH.
A limitation of the study is the number of donors and eye sec-
tions, and having only advanced stages of PDR included. The PDR
samples were from patients treated with photocoagulation; thus, the
possibility that the treatment had an impact on the results cannot be
fully excluded. The GLP-1R expression results were nevertheless con-
sistent across the different analyses performed. These results high-
light the need for caution when performing analyses of GLP-1R
expression, as apparently positive findings may be “false-positive” as a
result of lack of specificity of the analytical methods.
In conclusion, GLP-1Rs are rarely expressed in the normal human
eye and appear undetectable in advanced stages of PDR.
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FIGURE 2 Glucagon-like peptide-1
receptor (GLP-1R) protein and mRNA were
undetectable in proliferative diabetic
retinopathy (PDR). A, Retina with epiretinal
tissue with neovascularization from a
patient with PDR. B, GLP-1R
immunohistochemistry (IHC) from the same
area as in A. GLP-1R was not detected in
the retina or in areas of
neovascularization. C, GLP-1R mRNA was
likewise not detected in the eyes from
patients with PDR. D, Positive controls
[POLR2A (red) and PECAM1 (green)]. All
sections were counterstained with
haematoxylin. One eye section was stained
per patient. HE, haematoxylin and eosin; v,
blood vessel. Scale bars represent 250 μm
(B) and 100 μm (D), respectively. Scale bar
in B applies to A–B and scale bar in D to
C–D
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